Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

The prognostic value of tumour-stroma ratio in triple-negative breast cancer.

Moorman AM, Vink R, Heijmans HJ, van der Palen J, Kouwenhoven EA.

Eur J Surg Oncol. 2012 Apr;38(4):307-13. doi: 10.1016/j.ejso.2012.01.002. Epub 2012 Jan 20.

PMID:
22264965
2.

Systematic validation of specific phenotypic markers for in vitro polarized human macrophages.

Ambarus CA, Krausz S, van Eijk M, Hamann J, Radstake TR, Reedquist KA, Tak PP, Baeten DL.

J Immunol Methods. 2012 Jan 31;375(1-2):196-206. doi: 10.1016/j.jim.2011.10.013. Epub 2011 Oct 29.

PMID:
22075274
3.

Expression of ghrelin is correlated to a favorable outcome in invasive breast cancer.

Grönberg M, Fjällskog ML, Jirström K, Janson ET.

Acta Oncol. 2012 Mar;51(3):386-93. doi: 10.3109/0284186X.2011.631576. Epub 2011 Nov 9.

PMID:
22067021
4.

Chondroitin sulfate expression predicts poor outcome in breast cancer.

Svensson KJ, Christianson HC, Kucharzewska P, Fagerström V, Lundstedt L, Borgquist S, Jirström K, Belting M.

Int J Oncol. 2011 Dec;39(6):1421-8. doi: 10.3892/ijo.2011.1164. Epub 2011 Aug 17.

PMID:
21850370
5.

Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice.

Elkabets M, Gifford AM, Scheel C, Nilsson B, Reinhardt F, Bray MA, Carpenter AE, Jirström K, Magnusson K, Ebert BL, Pontén F, Weinberg RA, McAllister SS.

J Clin Invest. 2011 Feb;121(2):784-99. doi: 10.1172/JCI43757. Epub 2011 Jan 25.

6.

Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer.

Rexhepaj E, Jirstrom K, O'Connor DP, O'Brien SL, Landberg G, Duffy MJ, Brennan DJ, Gallagher WM.

BMC Cancer. 2010 Nov 23;10:639. doi: 10.1186/1471-2407-10-639.

7.

Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm.

Biswas SK, Mantovani A.

Nat Immunol. 2010 Oct;11(10):889-96. doi: 10.1038/ni.1937. Epub 2010 Sep 20. Review.

PMID:
20856220
8.

Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome.

Campbell MJ, Tonlaar NY, Garwood ER, Huo D, Moore DH, Khramtsov AI, Au A, Baehner F, Chen Y, Malaka DO, Lin A, Adeyanju OO, Li S, Gong C, McGrath M, Olopade OI, Esserman LJ.

Breast Cancer Res Treat. 2011 Aug;128(3):703-711. doi: 10.1007/s10549-010-1154-y. Epub 2010 Sep 15.

9.

Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival.

Onitilo AA, Engel JM, Greenlee RT, Mukesh BN.

Clin Med Res. 2009 Jun;7(1-2):4-13. doi: 10.3121/cmr.2009.825.

10.

Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma.

Jensen TO, Schmidt H, Møller HJ, Høyer M, Maniecki MB, Sjoegren P, Christensen IJ, Steiniche T.

J Clin Oncol. 2009 Jul 10;27(20):3330-7. doi: 10.1200/JCO.2008.19.9919. Epub 2009 Jun 15.

PMID:
19528371
11.

The role of myeloid cells in the promotion of tumour angiogenesis.

Murdoch C, Muthana M, Coffelt SB, Lewis CE.

Nat Rev Cancer. 2008 Aug;8(8):618-31. doi: 10.1038/nrc2444. Epub 2008 Jul 17. Review.

PMID:
18633355
13.

CD163 positive subsets of blood dendritic cells: the scavenging macrophage receptors CD163 and CD91 are coexpressed on human dendritic cells and monocytes.

Maniecki MB, Møller HJ, Moestrup SK, Møller BK.

Immunobiology. 2006;211(6-8):407-17. Epub 2006 Jul 20.

PMID:
16920480
15.

Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy.

Sica A, Schioppa T, Mantovani A, Allavena P.

Eur J Cancer. 2006 Apr;42(6):717-27. Epub 2006 Mar 7. Review.

PMID:
16520032
16.

Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial.

Jirström K, Rydén L, Anagnostaki L, Nordenskjöld B, Stål O, Thorstenson S, Chebil G, Jönsson PE, Fernö M, Landberg G.

J Clin Pathol. 2005 Nov;58(11):1135-42.

17.

Identification of molecular apocrine breast tumours by microarray analysis.

Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, Macgrogan G, Bergh J, Cameron D, Goldstein D, Duss S, Nicoulaz AL, Brisken C, Fiche M, Delorenzi M, Iggo R.

Oncogene. 2005 Jul 7;24(29):4660-71.

PMID:
15897907
18.

Expression of CD163 (hemoglobin scavenger receptor) in normal tissues, lymphomas, carcinomas, and sarcomas is largely restricted to the monocyte/macrophage lineage.

Nguyen TT, Schwartz EJ, West RB, Warnke RA, Arber DA, Natkunam Y.

Am J Surg Pathol. 2005 May;29(5):617-24.

PMID:
15832085
19.

NCBI GEO: mining millions of expression profiles--database and tools.

Barrett T, Suzek TO, Troup DB, Wilhite SE, Ngau WC, Ledoux P, Rudnev D, Lash AE, Fujibuchi W, Edgar R.

Nucleic Acids Res. 2005 Jan 1;33(Database issue):D562-6.

20.

Correlation of histological localization of tumor-associated macrophages with clinicopathological features in endometrial cancer.

Ohno S, Ohno Y, Suzuki N, Kamei T, Koike K, Inagawa H, Kohchi C, Soma G, Inoue M.

Anticancer Res. 2004 Sep-Oct;24(5C):3335-42.

Supplemental Content

Support Center